To operate within the exosome market, it is vital to assess novel opportunities for product development. The most developed market segment involves research products that utilize stem cell exosomes, with these tools being sold to researchers in laboratories worldwide. However, exosomes can also be commercialized as therapeutic agents, diagnostic tools, and cosmeceuticals. Additionally, manufacturing technologies are being developed to support exosome production.
Exosome Market Analysis
In this article:
- Research & Diagnostic Applications of Exosomes
- Evolution of Exosome Therapeutics
- Accelerating Interest in Exosome Manufacturing
Quick Facts About the Exosome Market
This article explores facts about the exosome market, including the growing role of exosome research products, as well as diagnostic and therapeutic applications.
Research & Diagnostic Applications of Exosomes
Although exosomes and extracellular vesicles (EVs) are being used predominantly within the research and life science fields, we will likely see an explosion in the development of research and clinical tools as more data is published on their applications. This will parallel the rapid growth seen in the consumer genetics market.
In 5-10 years, there will be a variety of clinical tools available to assess diseases, including various cancers, diabetes, neurodegenerative diseases, neural disorders, and more.
The example of Exosome Diagnostics’ entry into exosome-based diagnostics is a positive sign for diagnostics leveraging exosomes. Oasis Diagnostics is also doing fascinating work with salivary extracellular vesicles (EVs), exosomes, and other non-invasive diagnostics.
Exosome Diagnostics for Cancer Biomarkers
There is a prolific body of research exploring how exosomes can be leveraged as biomarkers to detect cancer and other emerging disease states without the need for biopsy or other invasive procedures. Because exosomes reflect properties of their cell source (the cell from which they were secreted), they can be used as powerful diagnostic tools. In one example involving a cancer stem cell population, a research team led by Dr. Bourkoula demonstrated that exosomes derived from glioma-associated stem cells (GASCs) support tumor growth and have a tumor-supporting phenotype.
Equipment and protocols to support exosome-based research are also being developed. For example, Beckman Coulter is actively marketing its instrumentation (via Google Adwords) to support standardized and automated exosome isolation, characterization, and sequencing of exosome-derived RNA.
Evolution of Exosome Therapeutics
In recent years, there has also been an evolution toward the use of exosomes as cell-free therapeutics.
Codiak BioSciences | Exosome Therapy
On the therapeutic front, various research groups are exploring ex vivo manipulation and subsequent reintroduction of exosome-based therapeutics. Despite substantial validation of this approach in preclinical settings, no exosome-based therapeutics have been approved for commercialization by a regulatory agency.
However, the success of Codiak BioSciences is very promising, because the company is developing a unique platform to utilize exosomes as therapeutics. The company was founded in late 2016 when the MD Anderson Cancer Center joined together with two venture capital firms and co-founder Dr. Eric Lander to launch the company, with $80 million in series A and B financing.
ExCoBio, Inc. | Anti-Aging Exosome Treatment
A “cosmeceutical” is a cosmetic product that has medicinal properties, most commonly, anti-aging properties. ExCoBio, Inc. is a market leader in the area of exosome-based cosmeceuticals, but other players are beginning to appear, particularly within East Asia.
ExoCoBio is a venture-backed startup that develops exosome-based cosmeceuticals and biopharmaceuticals for skin and tissue regeneration that is headquartered in South Korea.
Kimera Labs | Exosome Stem Cells Research
Kimera Labs is a biotechnology company with an FDA registered tissue facility that develops “umbilical cord and organ based exosome products for research and therapeutic purposes.” In addition to offering cosmeceutical products, such as its XOGLO™ skin therapy, it is exploring exosome methods and therapy protocols for use in treating burns, orthopedics, and inflammatory diseases.
The company has an incredible burn patient case study that can be seen here.
Accelerating Interest in Exosome Manufacturing
Although no contract manufacturing organization (CMO) has yet identified itself as a specialist in exosome manufacturing, this will likely occur as exosome-based therapeutics progress from academic research into clinical trials.
Exosome Market Growth
In August 2017, RoosterBio and Exopharm entered a partnership to develop techniques for the large-scale manufacture of clinical-grade exosomes, and Lonza expressed an intent to compete in this market. Additionally, the Australian biotech company VivaZome Therapeutics was awarded a grant of $2.18M in December 2017 to support a project titled,” Enabling Exosome Therapy: Developing an Advanced Manufacturing Process.”
Each of the areas described above represents exciting opportunities for the commercialization of stem cell exosomes, as well as exosomes derived from other cell types.
To learn more, view the “Market for Stem Cell Exosomes.”
What are your thoughts on the current exosome market? Share them in the comments below.
 Bourkoula E, Mangoni D, Ius T, Pucer A, Isola M, Musiello D, Marzinotto S, Toffoletto B, Sorrentino M, Palma A, et al. Glioma-associated stem cells: A novel class of tumor-supporting cells able to predict prognosis of human low-grade gliomas. Stem Cells. 2014;32:1239–1253. doi: 10.1002/stem.1605.
 ExoCoBio Inc. attracts Series A investment of US$11 million. [online] PRWeb. Available at: http://www.prweb.com/releases/2017/04/prweb14284662.htm [Accessed 11 Aug. 2017].